Inozyme PharmaINZY
About: Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Employees: 59
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
71% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 21
19% more capital invested
Capital invested by funds: $240M [Q2] → $285M (+$45M) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
0.12% less ownership
Funds ownership: 87.14% [Q2] → 87.02% (-0.12%) [Q3]
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 90 [Q2] → 89 (-1) [Q3]
39% less call options, than puts
Call options by funds: $22K | Put options by funds: $36K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Edward White 26% 1-year accuracy 37 / 142 met price target | 368%upside $14 | Buy Reiterated | 6 Nov 2024 |
Needham Joseph Stringer 31% 1-year accuracy 39 / 127 met price target | 669%upside $23 | Buy Reiterated | 6 Nov 2024 |
Wedbush David Nierengarten 38% 1-year accuracy 49 / 128 met price target | 402%upside $15 | Outperform Reiterated | 30 Sept 2024 |